Last reviewed · How we verify
aspirin and/or clopidogrel
Aspirin and clopidogrel are antiplatelet agents that inhibit platelet aggregation through different pathways to prevent blood clots.
Aspirin and clopidogrel are antiplatelet agents that inhibit platelet aggregation through different pathways to prevent blood clots. Used for Acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI), Secondary prevention of cardiovascular events post-myocardial infarction, Stroke prevention in patients with acute ischemic stroke or transient ischemic attack.
At a glance
| Generic name | aspirin and/or clopidogrel |
|---|---|
| Sponsor | Asan Medical Center |
| Drug class | Antiplatelet agent |
| Target | COX (aspirin); P2Y12 receptor (clopidogrel) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Aspirin irreversibly inhibits cyclooxygenase (COX), reducing thromboxane A2 production and platelet activation. Clopidogrel is a P2Y12 receptor antagonist that blocks ADP-induced platelet aggregation. Together, they provide dual antiplatelet therapy (DAPT) for synergistic antithrombotic effects.
Approved indications
- Acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI)
- Secondary prevention of cardiovascular events post-myocardial infarction
- Stroke prevention in patients with acute ischemic stroke or transient ischemic attack
Common side effects
- Bleeding (major and minor)
- Gastrointestinal bleeding
- Dyspepsia
- Intracranial hemorrhage
- Thrombotic thrombocytopenic purpura (TTP)
Key clinical trials
- The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis (PHASE4)
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
- Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI (PHASE4)
- Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial (PHASE3)
- Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- aspirin and/or clopidogrel CI brief — competitive landscape report
- aspirin and/or clopidogrel updates RSS · CI watch RSS
- Asan Medical Center portfolio CI